Factor analysis of predictive markers of response and resistance to primary chemo-endocrine treatment in elderly breast cancer (BC) patients

Factor analysis of predictive markers of response and resistance to primary chemo-endocrine treatment in elderly breast cancer (BC) patients

Show other versions (1)

Bibliographic Details
Main Authors:	Generali, D, Fox, S, Buffa, F, Berruti, A, Brizzi, M, Bonardi, S, Dogliotti, L, Harris, A, Bottini, A
Format:	Conference item
Published:	2006

Similar Items

Factor analysis of predictive markers of response and resistance to primary chemo-endocrine treatment in elderly breast cancer (BC) patients
by: Generali, D, et al.
Published: (2006)

Principal factor analysis of predictive markers of response and resistance to primary chemo-endocrine treatment in elderly breast cancer (BC) patients.
by: Generali, D, et al.
Published: (2006)

Phosphorylated ERalpha, HIF-1alpha, and MAPK signaling as predictors of primary endocrine treatment response and resistance in patients with breast cancer.
by: Generali, D, et al.
Published: (2009)

Effect of primary letrozole (LET) vs letrozole plus metronomic cyclophosphamide (LET-CYC) on Treg infiltration in ER plus ve breast cancer.
by: Fox, S, et al.
Published: (2006)

The prolyl hydroxylase enzymes are positively associated with hypoxia-inducible factor-1α and vascular endothelial growth factor in human breast cancer and alter in response to primary systemic treatment with epirubicin and tamoxifen.
by: Fox, S, et al.
Published: (2011)

The prolyl hydroxylase enzymes are positively associated with hypoxia-inducible factor-1α and vascular endothelial growth factor in human breast cancer and alter in response to primary systemic treatment with epirubicin and tamoxifen
by: Fox, S, et al.
Published: (2011)

Anti-angiogenic effect of tamoxifen combined with epirubicin in breast cancer patients
by: Mele, T, et al.
Published: (2010)

Anti-angiogenic effect of tamoxifen combined with epirubicin in breast cancer patients.
by: Mele, T, et al.
Published: (2010)

Regulation of hepatocyte growth factor activator inhibitor 2 by hypoxia in breast cancer.
by: Generali, D, et al.
Published: (2007)

Regulation of hepatocyte growth factor activator inhibitor 2 by hypoxia in breast cancer
by: Generali, D, et al.
Published: (2007)

Down-regulation of phosphatidylinositol 3'-kinase/AKT/molecular target of rapamycin metabolic pathway by primary letrozole-based therapy in human breast cancer.
by: Generali, D, et al.
Published: (2008)

Immunomodulation of FOXP3+ regulatory T cells by the aromatase inhibitor letrozole in breast cancer patients.
by: Generali, D, et al.
Published: (2009)

DOWN-REGULATION OF HYPOXIA INDUCIBILE FACTOR-1 alpha (HIF-1 alpha) EXPRESSION, THROUGH mTOR PATHWAY, BY LETROZOLE (FEMARA (R)) IN ER plus ve BREAST CANCER PATIENTS: CLINICAL IMPLICATIONS
by: Foroni, C, et al.
Published: (2009)

Changes of bone turnover markers and serum PTH after night or morning administration of zoledronic acid in breast cancer patients with bone metastases.
by: Generali, D, et al.
Published: (2008)

Molecular oncology and the neoadjuvant setting: the perfect blend for treatment personalization and clinical trial design.
by: Generali, D, et al.
Published: (2011)

Early breast cancer in elderly women: surgery or primary endocrine therapy?
by: Accurso A, et al.
Published: (2010-05-01)

Increased pathological complete response rate after a long-term neoadjuvant letrozole treatment in postmenopausal oestrogen and/or progesterone receptor-positive breast cancer.
by: Allevi, G, et al.
Published: (2013)

Increased pathological complete response rate after a long-term neoadjuvant letrozole treatment in postmenopausal oestrogen and/or progesterone receptor-positive breast cancer
by: Allevi, G, et al.
Published: (2013)

Neoadjuvant Chemo-Endocrine Therapy for Hormone Receptor Positive Breast Cancer: A Meta-Analysis
by: Zhen-Yu Li, et al.
Published: (2023-04-01)

Sentinel lymph node surgery after neoadjuvant chemotherapy in patients with T2 to T4, N0 and N1 breast cancer
by: Andreis, D, et al.
Published: (2016)

Quality of Life of Elderly and Senile Patients with Hormone Receptor Positive Breast Cancer Using Primary Endocrine Therapy
by: A. G. Manikhas, et al.
Published: (2022-05-01)

The role of ATF4 stabilization and autophagy in resistance of breast cancer cells treated with Bortezomib.
by: Milani, M, et al.
Published: (2009)

Endocrine and Neuroendocrine Tumors: A Special Issue
by: Alfredo Berruti, et al.
Published: (2022-10-01)

S100β as a serum marker in endocrine resistant breast cancer
by: Sara Charmsaz, et al.
Published: (2017-04-01)

The Value of Serum Biomarkers (Bc1, Bc2, Bc3) in the Diagnosis of Early Breast Cancer
by: Kemal Atahan, Hakan Küpeli, Serhat Gür, Türkan Yiğitbaşı, Yasemin Baskın, Seyran Yiğit, Mehmet Deniz, Atilla Çökmez, Ercüment Tarcan
Published: (2011-01-01)

Sarcopenia as a Prognostic Marker in Elderly Head and Neck Squamous Cell Carcinoma Patients Undergoing (Chemo-)Radiation
by: Erik Haehl, et al.
Published: (2022-11-01)

Editorial: Endocrine Frailty in the Elderly
by: Antonio Aversa, et al.
Published: (2019-09-01)

Analysis of TLR2 in Primary Endocrine Resistant of Breast Cancer
by: Yunmei Wang, et al.
Published: (2024-02-01)

Primary endocrine therapy of locally advanced breast cancer patients
by: Nešković-Konstantinović Zora B.
Published: (2003-01-01)

Angiogenin is up-regulated in the nucleus and cytoplasm in human primary breast carcinoma and is associated with markers of hypoxia but not survival.
by: Campo, L, et al.
Published: (2005)

Primary radio(chemo)therapy for esophageal cancer in elderly patients: are efficiency and toxicity comparable with younger patients?
by: Stefan Münch, et al.
Published: (2017-07-01)

To Chemo or Not to Chemo… That Is the Question
by: Maria Felisa Eva B. Martin, et al.
Published: (2023-08-01)

Endocrine markers in critical illness
by: Vaman Khadilkar, et al.
Published: (2017-01-01)

Early post-surgical recurrence of metastatic vertebral neuro-endocrine tumour treated effectively with chemo-radiotherapy
by: Kaliya-Perumal Arun-Kumar, et al.
Published: (2019-03-01)

CHEMO- AND TARGET THERAPY OF PATIENTS WITH BREAST CANCER WITH METASTATIC BRAIN LESIONS
by: D. R. Naskhletashvili, et al.
Published: (2015-04-01)

Synergistic activity of letrozole and sorafenib on breast cancer cells.
by: Bonelli, M, et al.
Published: (2010)

BNIP3 as a progression marker in primary human breast cancer; opposing functions in in situ versus invasive cancer.
by: Tan, E, et al.
Published: (2007)

Molecular markers in the CHART trial
by: Wilson, G, et al.
Published: (2005)

ADVANCES IN TARGETED THERAPY FOR BREAST CANCER (BC)
by: Gabriel N. Hortobagyi
Published: (2005-01-01)

LMTK3 confers chemo-resistance in breast cancer
by: Stebbing, Justin, et al.
Published: (2018)